Glioma Risk Lower with Elevated Blood Sugar
|
By LabMedica International staff writers Posted on 16 May 2017 |

Image: New research suggests that there may be a link between blood sugar and glioma (Photo courtesy of MNT).
While many cancers are more common among those with diabetes, cancerous brain tumors called gliomas are less common among those with elevated blood sugar and diabetes.
Glioma is a heterogeneous primary brain tumor for which there is no treatment that ensures long-term survival and patients diagnosed with the most common adult form of this tumor, glioblastoma, survive on average only 14 months.
An international team of scientists led by those at the Ohio State University evaluated blood sugar and diabetes data and its relationship to subsequent development of brain cancer and found that those with elevated blood sugar and diabetes had a lower risk of developing glioma. They used data from the Apolipoprotein MOrtality RISk (AMORIS) (n = 528,580) and the Metabolic syndrome and Cancer project (Me-Can) cohorts (n = 269,365). They identified individuals who were followed for a maximum of 15 years after their first blood glucose test until glioma diagnosis, death, emigration or the end of follow-up.
They conducted an exploratory analysis of the 51 glioma cases using the Me-Can data set with multiple measurements to determine whether glucose values equal to or less than 7.0 mmol/L varied with the number of measurements or time between the blood glucose test and glioma diagnosis. They found that fasting and non-fasting glucose dose-response relationships were similar allowing them to combine data from these two groups.
They found that the relative proportions of male and female total glioma cases differ between the cohorts (in AMORIS 65% are men; in Me-Can 52%), as does fasting status (in AMORIS 61% of blood was drawn when total glioma cases were fasting; in Me-Can all blood samples were collected from fasting participants). Pre-diagnostic blood glucose levels were inversely related to glioma risk and pre-diagnostic diabetes. During the year before diagnosis, blood glucose was inversely associated with glioma in the AMORIS but not the Me-Can cohort. This AMORIS result is consistent with their hypothesis that excess glucose consumption by the preclinical tumor accounts for the inverse association between blood glucose and glioma.
Judith Schwartzbaum, PhD, a professor and lead author of the study said, “Diabetes and elevated blood sugar increase the risk of cancer at several sites including the colon, breast and bladder. But in this case, these rare malignant brain tumors are more common among people who have normal levels of blood glucose than those with high blood sugar or diabetes.” The study was published on May 3, 2017, in the journal Scientific Reports.
Glioma is a heterogeneous primary brain tumor for which there is no treatment that ensures long-term survival and patients diagnosed with the most common adult form of this tumor, glioblastoma, survive on average only 14 months.
An international team of scientists led by those at the Ohio State University evaluated blood sugar and diabetes data and its relationship to subsequent development of brain cancer and found that those with elevated blood sugar and diabetes had a lower risk of developing glioma. They used data from the Apolipoprotein MOrtality RISk (AMORIS) (n = 528,580) and the Metabolic syndrome and Cancer project (Me-Can) cohorts (n = 269,365). They identified individuals who were followed for a maximum of 15 years after their first blood glucose test until glioma diagnosis, death, emigration or the end of follow-up.
They conducted an exploratory analysis of the 51 glioma cases using the Me-Can data set with multiple measurements to determine whether glucose values equal to or less than 7.0 mmol/L varied with the number of measurements or time between the blood glucose test and glioma diagnosis. They found that fasting and non-fasting glucose dose-response relationships were similar allowing them to combine data from these two groups.
They found that the relative proportions of male and female total glioma cases differ between the cohorts (in AMORIS 65% are men; in Me-Can 52%), as does fasting status (in AMORIS 61% of blood was drawn when total glioma cases were fasting; in Me-Can all blood samples were collected from fasting participants). Pre-diagnostic blood glucose levels were inversely related to glioma risk and pre-diagnostic diabetes. During the year before diagnosis, blood glucose was inversely associated with glioma in the AMORIS but not the Me-Can cohort. This AMORIS result is consistent with their hypothesis that excess glucose consumption by the preclinical tumor accounts for the inverse association between blood glucose and glioma.
Judith Schwartzbaum, PhD, a professor and lead author of the study said, “Diabetes and elevated blood sugar increase the risk of cancer at several sites including the colon, breast and bladder. But in this case, these rare malignant brain tumors are more common among people who have normal levels of blood glucose than those with high blood sugar or diabetes.” The study was published on May 3, 2017, in the journal Scientific Reports.
Latest Clinical Chem. News
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
- Prostate Cancer Markers Based on Chemical Make-Up of Calcifications to Speed Up Detection
- Breath Test Could Help Detect Blood Cancers
- ML-Powered Gas Sensors to Detect Pathogens and AMR at POC
- Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation
- Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
- New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs

- New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
- Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Genetic Marker to Help Children with T-Cell Leukemia Avoid Unnecessary Chemotherapy
About 400 children in the UK are diagnosed with acute lymphoblastic leukemia (ALL) each year, with roughly 15% presenting with a more aggressive T-ALL subtype. While the standard approach is a four-week... Read more
Four-Gene Blood Test Rules Out Bacterial Lung Infection
Lower respiratory tract infections (LRTIs) are among the most common reasons for antibiotic prescriptions, yet distinguishing bacterial infections from viral ones remains notoriously difficult.... Read more
New PCR Test Improves Diagnostic Accuracy of Bacterial Vaginosis and Candida Vaginitis
Bacterial vaginosis (BV) impacts approximately 25% of women of reproductive age, while up to 75% of women experience candida vaginitis (CV) at least once in their lifetime. Vaginal symptoms are one of... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








